BACKGROUND: The mechanisms governing extracellular matrix degradation and smooth muscle cell (SMC) loss in the ascending aorta of bicuspid aortic valve (BAV) patients are unknown. We recently reported that expression and induction of metallothionein, a reactive oxygen species scavenger, is reduced in BAV ascending aortic aneurysms relative to nonaneurysmal patients. METHODS: Tissue and primary SMCs from patients with and without thoracic aortic aneurysms and metallothionein-null and wild-type mice were analyzed for cell viability, vascular endothelial growth factor (VEGF), and type I collagen gene expression during exposure to reactive oxygen species. RESULTS: The BAV SMCs and metallothionein -/- mice failed to induce VEGF under conditions of oxidative stress in vitro. Exogenous VEGF restored resistance to oxidative stress in BAV SMCs to normal. Type I collagen gene induction was increased in BAV aorta. CONCLUSIONS: Lack of VEGF induction during exposure to reactive oxygen species suggest that the oxidative stress response is faulty upstream of metallothionein and VEGF in BAV SMCs. Improvement of cell viability with VEGF treatment suggests that the deficient pathway can be rescued by VEGF. Increased type I collagen in BAV suggests that lack of metallothionein/VEGF activation in response to reactive oxygen species may play a role in extracellular matrix homeostasis of the ascending aorta. These data continue to support our hypothesis that BAV SMCs lack sufficient resistance to reactive oxygen species to maintain extracellular matrix homeostasis, which imparts a predisposition to thoracic aortic aneurysms.
BACKGROUND: The mechanisms governing extracellular matrix degradation and smooth muscle cell (SMC) loss in the ascending aorta of bicuspid aortic valve (BAV) patients are unknown. We recently reported that expression and induction of metallothionein, a reactive oxygen species scavenger, is reduced in BAV ascending aortic aneurysms relative to nonaneurysmal patients. METHODS: Tissue and primary SMCs from patients with and without thoracic aortic aneurysms and metallothionein-null and wild-type mice were analyzed for cell viability, vascular endothelial growth factor (VEGF), and type I collagen gene expression during exposure to reactive oxygen species. RESULTS: The BAV SMCs and metallothionein -/- mice failed to induce VEGF under conditions of oxidative stress in vitro. Exogenous VEGF restored resistance to oxidative stress in BAV SMCs to normal. Type I collagen gene induction was increased in BAV aorta. CONCLUSIONS: Lack of VEGF induction during exposure to reactive oxygen species suggest that the oxidative stress response is faulty upstream of metallothionein and VEGF in BAV SMCs. Improvement of cell viability with VEGF treatment suggests that the deficient pathway can be rescued by VEGF. Increased type I collagen in BAV suggests that lack of metallothionein/VEGF activation in response to reactive oxygen species may play a role in extracellular matrix homeostasis of the ascending aorta. These data continue to support our hypothesis that BAV SMCs lack sufficient resistance to reactive oxygen species to maintain extracellular matrix homeostasis, which imparts a predisposition to thoracic aortic aneurysms.
Authors: Joseph E Pichamuthu; Julie A Phillippi; Deborah A Cleary; Douglas W Chew; John Hempel; David A Vorp; Thomas G Gleason Journal: Ann Thorac Surg Date: 2013-09-07 Impact factor: 4.330
Authors: Alkiviadis Tsamis; Julie A Phillippi; Ryan G Koch; Salvatore Pasta; Antonio D'Amore; Simon C Watkins; William R Wagner; Thomas G Gleason; David A Vorp Journal: J Biomech Date: 2013-09-11 Impact factor: 2.712
Authors: Marie Billaud; Julie A Phillippi; Mary P Kotlarczyk; Jennifer C Hill; Bradley W Ellis; Claudette M St Croix; Nadiezhda Cantu-Medéllin; Eric E Kelley; Thomas G Gleason Journal: J Thorac Cardiovasc Surg Date: 2017-05-25 Impact factor: 5.209
Authors: Alkiviadis Tsamis; Siladitya Pal; Julie A Phillippi; Thomas G Gleason; Spandan Maiti; David A Vorp Journal: J Biomech Date: 2014-10-30 Impact factor: 2.712
Authors: Alkiviadis Tsamis; Julie A Phillippi; Ryan G Koch; Patrick G Chan; Jeffrey T Krawiec; Antonio D'Amore; Simon C Watkins; William R Wagner; David A Vorp; Thomas G Gleason Journal: J Thorac Cardiovasc Surg Date: 2016-02-13 Impact factor: 5.209
Authors: Julie A Phillippi; Benjamin R Green; Michael A Eskay; Mary P Kotlarczyk; Michael R Hill; Anne M Robertson; Simon C Watkins; David A Vorp; Thomas G Gleason Journal: J Thorac Cardiovasc Surg Date: 2013-06-12 Impact factor: 5.209
Authors: Mary P Kotlarczyk; Marie Billaud; Benjamin R Green; Jennifer C Hill; Sruti Shiva; Eric E Kelley; Julie A Phillippi; Thomas G Gleason Journal: Ann Thorac Surg Date: 2016-06-07 Impact factor: 4.330
Authors: Michael A Borger; Paul W M Fedak; Elizabeth H Stephens; Thomas G Gleason; Evaldas Girdauskas; John S Ikonomidis; Ali Khoynezhad; Samuel C Siu; Subodh Verma; Michael D Hope; Duke E Cameron; Donald F Hammer; Joseph S Coselli; Marc R Moon; Thoralf M Sundt; Alex J Barker; Michael Markl; Alessandro Della Corte; Hector I Michelena; John A Elefteriades Journal: J Thorac Cardiovasc Surg Date: 2018-08 Impact factor: 5.209
Authors: Carmen Rueda-Martínez; Oscar Lamas; María José Mataró; Juan Robledo-Carmona; Gemma Sánchez-Espín; Manuel Jiménez-Navarro; Miguel Such-Martínez; Borja Fernández Journal: PLoS One Date: 2014-05-19 Impact factor: 3.240